中国临床药理学杂志2017，Vol.33Issue(16)：1540-1542,3.DOI:10.13699/j.cnki.1001-6821.2017.16.007
奥沙利铂联合替吉奥治疗晚期结肠癌患者的临床疗效与安全性
Clinical trial and safety of oxaliplatin combined with tegafur in the treatment of advanced colorectal cancer patients
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of oxaliplatin combined with tegafur in the treatment of advanced colorectal cancer(ACC).Methods Forty-eight cases of patients with ACC were randomly divided into the control group and treatment group,24 cases in each group.The control group was given intravenous infusion of oxaliplatin 130 mg· m-2 + oral capecitabine1 g · m-2,bid;the treatment group was given intravenous infusion of oxaliplatin130 mg · m-2 + tegafur 40 mg · m-2,bid;two groups of patients with a cycle of 21 days,a total of 4 cycles of treatment.Before and after treatment,The levels of serum cancer embryonic antigen (CEA),alpha fetal protein (AFP),carbohydrate antigen 19-9 (CA19-9),cytoplasmic thymidine kinase 1 (TK1) were determined in order to compare between the two groups.Results After treatment,the serum levels of CEA,AFP in control group and treatment group were (21.45 ± 3.06),(15.34 ± 2.18);(9.74 ± 1.32),(5.11 ±0.73)ng · mL-1;the serum levels of CA19-9 in the two groups were (162.43 ± 21.45),(135.68 ± 17.45) U · mL-1;the serum levels of TK1 in the two groups were (1.98 ± 0.26),(1.11 ± 0.14)pmol · L-1.Compared with the control group,the serum levels of CEA,AFP,CA19-9 and TK1 were lowerer than treatment group with significantly(all P ＜0.05).The efficiency of the treatment group (83.33％) was significantly higher than that of the control group (66.66％,P ＜ 0.05).The incidence of adverse drugs reactions of the treatment group (58.33％) was significantly lower than that of the control group (79.17％,P ＜0.05),the results were statistically significant.Conclusion The oxaliplatin combined with tegafur can significantly reduce the serum levels of CEA,AFP,CA19-9 and TK1 in patients with advanced colorectal cancer,improve clinical efficacy and safety.关键词
奥沙利铂/替吉奥/晚期结肠癌/癌胚抗原Key words
oxaliplatin/tegafur/advanced colorectal cancer/cancer embryonic antigen分类
医药卫生引用本文复制引用
孙翠玲,徐晓宇,高莹莹,田添,李峰..奥沙利铂联合替吉奥治疗晚期结肠癌患者的临床疗效与安全性[J].中国临床药理学杂志,2017,33(16):1540-1542,3.基金项目
阜阳市科学技术奖授奖技术基金资助项目(2014-2-26) （2014-2-26）
